Indoco Remedies received EU GMP certification from the UK Health Regulator for its sterile manufacturing facility (Plant II) at Verna, Goa. The company also stated that this is an outcome from the last successful inspection conducted by UK MHRA from September 16 to 20, 2019.

According to Ms. Aditi Kare Panandikar, Managing Director of Indoco Remedies Ltd., this positive development is very essential for the company. Also the receipt of EU GMP certification from UK MHRA for the company’s sterile manufacturing unit is encouraging and it also reflects immense learning and adaptation of a compliant culture by the technical team of Indoco Remedies.

Indoco Remedies Ltd. is a Mumbai headquartered fully integrated, research-oriented pharmaceutical company with presence across 55 countries. The pharma company which has around 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by recent technologies and R∧D Centre and a CRO facility. The company’s facilities have been approved by USFDA, UK-MHRA, TGA-Australia, PMDA-Japan, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian as well as international markets. It has a strong brand portfolio in various therapeutic segments including respiratory, anti-infective, dental care, pain management, gastro-intestinal, ophthalmic, cardiovascular, etc.

On Monday, the stock of the company closed at Rs 153, up by 3.03 per cent or Rs. 4.5 per share. The intraday high is Rs. 157.5 and intraday low is Rs 148.8. The 52-week high is Rs 230.5 and 52-week low is Rs 133.10 on BSE.